Fox Business - The Power to Prosper
Search Site

Bristol-Myers Squibb

Eli Lilly CEO: 2015 is a key transition year for us

Eli Lilly CEO John Lechleiter discusses new products, 2015 outlook, its Alzheimer’s disease program and animal health division.

Read More

  1. Pfizer Could See Value in AstraZeneca Pipeline

    Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound ($101 billion) takeover approach was rejected, since a deal coul...

  2. Investors: Brace for a Turbulent Second Quarter

    Fasten your seat belts. The second quarter is expected to be a bumpy ride.After a volatile first quarter for stocks that ended with the S&P 500 advancing a measly 1....

  3. GSK Stops Lung Cancer Vaccine Trial

    GlaxoSmithKline Plc (GSK) has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-g...

  4. Novo Nordisk Upgraded to 'Buy'

    Novo Nordisk (NYSE:NVO) was handed an upgrade to "buy" from "hold" on Tuesday from Austria's Erste Group, helping to boost its shares 1%.The Denmark-based drug giant...

  5. FDA Gives BMY Hep-C Drug 'Breakthrough' Status

    Bristol-Myers Squibb's (NYSE:BMY) investigational treatment for hepatitis C infection was awarded "breakthrough therapy designation" on Monday by U.S. drug regulator...

  6. AstraZeneca Says Generics to Dent '14 Profits

    AstraZeneca expects earnings to keep falling in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from ...

  7. Investors Brace for Bear Market

    Many of the major equity market averages are down more than 5% from their recent highs and in a pullback. The concern now among many investors is that continued sell...

  8. Bristol -Myers 4Q Earnings Beat the Street

    Bristol-Myers Squibb (NYSE:BMY) reported a 21% drop in its fourth-quarter profit, a year after the drug company logged a significant tax benefit.Bristol-Myers said F...

  9. Stock Futures Slide as Emerging-Market Fears Swell

    Wall Street was setting up for an bumpy open as stock futures pushed lower on Friday, looking set to extend sharp losses logged the prior session after several Asian...

  10. AstraZeneca Forecasts Faster Return To Growth

    AstraZeneca expects new drugs and a recent diabetes deal to offset a wave of patent expiries and return it to growth faster than analysts predict, with 2017 revenue ...

  11. Lexicon Pharma Cuts 45% Workforce, CEO to Leave

    Lexicon Pharmaceuticals Inc said its chief executive would leave and it would cut its workforce by about 45 percent, as it moves its focus away from drug discovery t...

  12. AstraZeneca to Buy Bristol's Stake in Venture

    AstraZeneca (NYSE:AZN) agreed on Thursday to buy Bristol-Myers Squibb's (NYSE:BMY) stake in their diabetes joint venture for up to $4.1 billion.The London-based biop...

  1. Bristol-Myers Squibb 3Q earnings beat expectations

    Earnings HQ: FBN’s Lori Rothman beaks down Bristol-Myers Squibb ’s third-quarter earnings report.

  2. The health-care stocks to boost your portfolio

    Rehmann Financial Principal Joe Heider on the health-care stocks to watch.

  3. Health care sector drags on the S&P

    FBN’s Liz MacDonald with an update on stocks.

  4. Pfizer, AstraZeneca deal still alive?

    Argus Research president John Eade and JPMorgan Funds Chief Global Strategist David Kelly on whether AstraZeneca will re-engage with Pfizer.

  5. Bristol-Myers Squibb 1Q earnings

    Earnings HQ: FBN’s Lori Rothman breaks down Bristol-Myers Squibb ’s first-quarter earnings report.

  6. European shares move higher on M&A talks

    BGC Partners’ Mike Ingram with the latest on the European markets.

  7. What to expect from pharma

    Robert W. Baird & Co. senior analyst Brian Skorney on what investors can expect from pharma in the second quarter.

‹ Prev12345Next ›
Freebase CC-BY
Source: Bristol-Myers Squibb on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL